Episodes
-
In this episode Karl Freemyer, BD director at FIECON, is speaking with Emma Chaffin about her experience living with the metastatic breast cancer as a biopharmaceutical executive.
Emma is a resilient breast cancer survivor who was diagnosed with stage 4 breast cancer five years ago at the age of 41. Facing a daunting prognosis and a treatment plan focused on palliative care, she defied the odds, with only a 22% chance of surviving five years. -
Von Hippel-Lindau syndrome (VHL), is an inherited condition that brings about tumors in various organs, particularly hemangioblastomas, which are blood vessel tumors found in the brain, spinal cord, and retina.
Listen to FIECON's latest 'Patient Perspectives' podcast with Lauren Weinberg, Senior Associate at FIECON, talking to Frankie Bryant about her journey living with VHL and the impact it has had.
-
Episodes manquant?
-
In this podcast, Lily Mumford talks to Lauren Weinberg, Senior Associate at FIECON, about her patient journey, experience living with LHON, and how losing her vision has impacted her life.
Leber hereditary optic neuropathy (LHON) is a rare condition that primarily affects young adults. It causes painless vision loss, typically starting in one eye and later affecting the other eye within a few weeks. Some individuals with LHON may also experience rare neurological problems like nerve issues, tremors, muscle weakness, and movement disorders.
LHON is caused by changes in mitochondrial DNA and is inherited through the maternal line. It is a rare disease affecting about 1 in 50,000 people. Many carriers of LHON do not experience significant vision loss.
However, males are four to five times more likely to lose vision than females. The annual incidence of vision loss in LHON is extremely low, around 1 in 10 million.
-
In this podcast, David Robins talks to Lauren Weinberg, Senior Associate at FIECON, about the patient journey, his experience as the father of Lexi who lives with Fibrodysplasia Ossificans Progressiva (FOP), and as a family after the FOP diagnosis.
FOP is an ultra-rare genetic condition and is one of the most debilitating conditions known to medicine. FOP causes the soft connective tissue of the body to turn into new bone. When that occurs over or near joints, or within a muscle, it restricts the person’s movements. This new bone, or ossification, can mean that the sufferer is eventually no longer able to move the joint. Once movement has been lost in a part of the body, it is not possible to remove the new bone as that can aggravate the FOP and trigger further bone growth.
FOP is characterised by congenital malformations of the big toes and progressive heterotopic ossification (HO) in specific anatomic patterns. FOP is the most catastrophic disorder of HO in humans. Flare-ups are episodic; immobility is cumulative. A common mutation in activin receptor IA (ACVR1), a bone morphogenetic protein (BMP) type I receptor, exists in all sporadic and familial cases with a classic presentation of FOP.There is currently no treatment for FOP so investigating all avenues of research and finding more FOP doctors, who are willing to be educated about FOP, is essential.
-
Erika Stariha is the mother of the first child in Slovenia diagnosed with SATB2-associated syndrome (SAS), as well as the founder and president of SATB2-Europe.
SATB2 Europe's aim is:
“To improve quality of life for individuals with SATB2 syndrome through discovery and development of targeted treatments and enhanced availability of appropriate care”.
SATB-2 associated (also known as chromosome 2q32-q33 deletion syndrome or Glass syndrome) is a rare genetic syndrome caused by mutations in the SATB-2 gene leading to developmental delays, intellectual disability, and speech and language difficulties.
The main symptoms can be remembered using the acronym S.A.T.B.2 :
S = Severe speech anomaliesA = Abnormalities of the palateT = Teeth anomaliesB = Behavioral issues with or without Bone or Brain anomaliesIn this podcast, Amanda Hansson Hedblom, Senior Associate at FIECON, talks to Erika Stariha about the patient journey and her experiences as both a parent of a child with SAS and as a patient advocacy leader. -
Juliette Vila Sinclair-Spence is a passionate Acanthamoeba keratitis (AK) Warrior and Rare Disease Patient Advocate as well as the Founder and Chairwoman of Acanthamoeba keratitis (AK) Eye Foundation. With her patient voice, she brings personal and first-hand experience of what it means to be affected by Acanthamoeba keratitis as well as its aftermath.
Her goal is to raise awareness about the rare disease Acanthamoeba keratitis by educating contact lens users (Contact lens and water don’t mix!), eye professionals to stop misdiagnosing Acanthamoeba keratitis, understand the impact the disease has, providing the right medical treatment (refer to an expert), support like pain management (excruciating pain) as well as mental support (depression) and encourage all contact lens manufacturers that a “No water" label on all packaging would help the goal.
In this podcast, Guy Lacey, Manager at FIECON, talks to Juliette about her patient journey since she contracted Acanthamoeba keratitis in 2016 and shares the details of her long and arduous journey to diagnosis and finally treatment. She has devoted much of her time to help others learn more about this disease and has became an advocate for patients, families and providers by creating the Acanthamoeba Keratitis (AK) Eye Foundation.Acanthamoeba keratitis is a rare but often devastating ocular condition that can lead to severe vision impairment, corneal transplantation, and even enucleation. It is caused by a free living amoeba that is typically found in soil and water, including tap water.
The main risk factor for AK is contact lens wear. AK presents initially with a high degree of pain, often out of proportion to the clinical signs observed. Many times, this condition is misdiagnosed as herpes simplex keratitis.
Our innate immune response can fight the infection, but once the amoebas have breached the corneal epithelium, it is difficult for the immune system to fight these parasites due to the fact the cornea is an immune-privileged tissue. Cysts can remain in a dormant state on corneal tissue for close to 3 years making recurrent infection possible. -
José Ángel Aibar became involved in the activities of the Dravet Syndrome Foundation, shortly after one of his sons was diagnosed with Dravet syndrome. He has served as President and CEO since June 2018.
José is also a member of several rare disease and epilepsy working groups, such as Epag EpiCARE and the Eurordis Digital and Data Advisory Group, as well as a member of the advisory committee of several international projects. and from the industry.
The Dravet Foundation was started with the aim of promoting, encouraging and connecting the world's leading research centers on Dravet syndrome and other related diseases. The aim is find a drug within three years that eliminates the symptoms and allows us to preserve the cognitive state of patients until a definitive solution for the disease is found.
In this podcast, Jamshaed Siddiqui, Manager at FIECON, talks to José Ángel Aibar about the patient journey and his experiences as both a parent of a child with Dravet syndrome and as a patient advocacy leader.
Dravet syndrome is a rare and catastrophic form of intractable epilepsy that begins in the first year of life, with an estimated incidence of 1 in 22,000 births.
Dravet syndrome is characterised by frequent, prolonged seizures that can be triggered by high body temperature (hyperthermia) and periods of illness. As well as seizures, common symptoms include mobility, behavioural, and cognitive abnormalities that develop as the child gets older.
There is no cure for Dravet syndrome. Early diagnosis and treatment may minimise seizure frequency and intensity, but few patients achieve seizure freedom. Without treatment, individuals will continue to have frequent seizures and can suffer from seizure-related accidents and increased risk of mortality.
As a rare disease, Dravet syndrome can be challenging for doctors to detect, and diagnosis is typically supported by genetic testing in children who are suspected of having, or at risk for, the condition but may also be diagnosed based on symptoms. -
World Orphan Drug Congress panel discussion November 2021
Karl Freemyer, Head of Business Development - FIECON (host)Martin Schuchardt, Director of Pricing and Market Access - FIECONSimon Eade, Vice president of Worldwide global strategy - Janssen Oriol Sola-Morales, CEO of Health Innovation Technology Transfer Eric Low, CEO - Eric Low Consulting
"Access for rare diseases - how to navigate conflict, compromise and collaboration" with panellists - -
Pompe disease is a rare (estimated at 1 in every 40,000 births), inherited and often fatal disorder that disables the heart and skeletal muscles. It is caused by mutations in a gene that makes an enzyme called acid alpha-glucosidase (GAA). Normally, the body uses GAA to break down glycogen, a stored form of sugar used for energy.
Infantile Pompe disease is the result of complete or near complete deficiency of GAA. Symptoms begin in the first months of life, with feeding problems, poor weight gain, muscle weakness, floppiness, and head lag. Respiratory difficulties are often complicated by lung infections. The heart is grossly enlarged. Many infants with Pompe disease also have enlarged tongues.
Without enzyme replacement therapy, the hearts of babies with infantile onset Pompe disease progressively thicken and enlarge.
Most babies die from cardiac or respiratory complications before their first birthday.Juvenile/Adult Pompe disease is the result of a partial deficiency of GAA. The onset can be as early as the first decade of childhood or as late as the sixth decade of adulthood. The primary symptom is muscle weakness progressing to respiratory weakness and death from respiratory failure after a course lasting several years. The heart is usually not involved.
In general, the later the age of onset, the slower the progression of the disease. Ultimately, the prognosis is dependent upon the extent of respiratory muscle involvement.
A diagnosis of Pompe disease can be confirmed by screening for the common genetic mutations or measuring the level of GAA enzyme activity in a blood sample.
Once Pompe disease is diagnosed, testing of all family members and a consultation with a professional geneticist are recommended. Carriers are most reliably identified via genetic mutation analysis. -
Chris and Helen Bedford - Gay are the founders and patient advocacy leaders at FOP Friends charity. In 2009 their first child, Oliver, was diagnosed with FOP, aged just one.
FOP Friends’ aim is to further research into Fibrodysplasia Ossificans Progressiva (FOP) and related conditions by supporting current and future research projects.
In this podcast they talk to us about the patient journey and their experiences as both parents of a child with FOP and patient advocacy leaders.FOP is an ultra-rare disabling genetic condition and is one of the most disabling conditions known to medicine. FOP causes the soft connective tissue of the body to turn into new bone. When that occurs over or near joints, or within a muscle, it restricts the person’s movements. This new bone, or ossification, can mean that the sufferer is no longer able to move the joint. Once movement has been lost in a part of the body, it is not possible to remove the new bone as that can aggravate the FOP and trigger further bone growth.
FOP is characterised by congenital malformations of the big toes and progressive heterotopic ossification (HO) in specific anatomic patterns. FOP is the most catastrophic disorder of HO in humans. Flare-ups are episodic; immobility is cumulative. A common mutation in activin receptor IA (ACVR1), a bone morphogenetic protein (BMP) type I receptor, exists in all sporadic and familial cases with a classic presentation of FOP.
Chris and Helen discuss how educating the wider population ensuring an early diagnosis, is key to preventing further heterotopic ossification.
There is currently no treatment for FOP. As a patient organisation investigating all avenues of research and finding more FOP doctors, who are willing to be educated about FOP, is essential. -
Vince Nicholas and Paul Pozzo are patient advocacy leaders at the UK ATTR amyloidosis Patient Association. Each live with a variant of the rare disease amyloidosis; ATTR (transthyretin) amyloidosis and wild-type amyloidosis, respectively.
In this podcast they talk to us about their patient journey and their experiences as both patients and patient advocacy leaders.Amyloidosis is a protein disorder in which proteins change shape, then bind together and form amyloid fibrils which deposit in organs.
As amyloid fibrils build up, the tissues and organs may not work as well as they should. Amyloidosis is a long term (chronic) disease. The severity of the disease depends on which organs are affected which can be the heart, blood, or liver,which may necessitate a liver transplant.Vince and Paul discuss how educating the wider population on the symptoms of amyloidosis, ensuring an early diagnosis, is THE key to managing the disease before it becomes too advanced.
-
In this podcast, Patient X talks to us about her patient journey and her experiences, as both a patient and patient advocacy leader.
Five years ago, a high impact event led to Patient X being diagnosed with chronic migraines. Patient X is a volunteer with several migraine and headache non-profit organisations, she has a Master of Public Health and Epidemiology and works as a health economics and outcomes research worker.
Migraines have many manifestations and according to the International classification of headache disorders, more than 50 types, these include migraine pain with and without aura, chronic migraine, menstrual migraine, hemiplegic migraine - a rare type involving temporary weakness on one side of the body, migraine with brain stem aura, vestibular migraine, predominant vertigo, abdominal migraine, cluster headaches, and many more.
There is much more than just head pain in a migraine or headache, the heterogeneity of diseases and social determinants of health for example, race, urbanicity, and access to health care providers makes it hard to consistently identify migraine patients.
Advocacy is key to combating the burden of migraines. There is stigma attached to migraine disease related to the historical view that it was a 'hysterical woman's problem' which was not serious and could be cured by simply 'popping a pill’.
Educating the wider population about the wide variety of symptoms of migraine and removing that stigma is essential in reducing both the clinical and economic burden of the disease.
